RG Melton

992 total citations
17 papers, 748 citations indexed

About

RG Melton is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Molecular Biology. According to data from OpenAlex, RG Melton has authored 17 papers receiving a total of 748 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Radiology, Nuclear Medicine and Imaging, 6 papers in Oncology and 5 papers in Molecular Biology. Recurrent topics in RG Melton's work include Monoclonal and Polyclonal Antibodies Research (12 papers), Radiopharmaceutical Chemistry and Applications (6 papers) and Cancer Research and Treatments (4 papers). RG Melton is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (12 papers), Radiopharmaceutical Chemistry and Applications (6 papers) and Cancer Research and Treatments (4 papers). RG Melton collaborates with scholars based in United Kingdom, United States and Germany. RG Melton's co-authors include R.F. Sherwood, F Searle, K D Bagshawe, Springer Cj, Pari Antoniw, SK Sharma, Caroline J. Springer, Robert I. Dowell, D C Blakey and A. Zoubek and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Journal of Medicinal Chemistry.

In The Last Decade

RG Melton

17 papers receiving 711 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
RG Melton United Kingdom 12 414 368 190 134 123 17 748
T W Strickland United States 10 443 1.1× 112 0.3× 57 0.3× 72 0.5× 88 0.7× 10 871
Malaya Bhattacharya United States 14 348 0.8× 169 0.5× 54 0.3× 49 0.4× 46 0.4× 31 598
Paul J. Kleindl United States 14 378 0.9× 111 0.3× 214 1.1× 207 1.5× 41 0.3× 19 697
H.J. Schoemaker United States 12 557 1.3× 149 0.4× 205 1.1× 50 0.4× 30 0.2× 20 946
Earl F. Albone United States 17 294 0.7× 180 0.5× 241 1.3× 144 1.1× 43 0.3× 35 729
C. A. Waller United Kingdom 12 293 0.7× 98 0.3× 107 0.6× 46 0.3× 37 0.3× 18 675
D. Deprez-De Campeneere Belgium 8 289 0.7× 98 0.3× 218 1.1× 84 0.6× 23 0.2× 9 609
Samantha Lien Australia 11 675 1.6× 528 1.4× 101 0.5× 24 0.2× 44 0.4× 15 934
Linda Simpson‐Herren United States 15 324 0.8× 91 0.2× 288 1.5× 29 0.2× 27 0.2× 29 794
Sudhir Shah United States 15 227 0.5× 250 0.7× 147 0.8× 31 0.2× 84 0.7× 31 689

Countries citing papers authored by RG Melton

Since Specialization
Citations

This map shows the geographic impact of RG Melton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by RG Melton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites RG Melton more than expected).

Fields of papers citing papers by RG Melton

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by RG Melton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by RG Melton. The network helps show where RG Melton may publish in the future.

Co-authorship network of co-authors of RG Melton

This figure shows the co-authorship network connecting the top 25 collaborators of RG Melton. A scholar is included among the top collaborators of RG Melton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with RG Melton. RG Melton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Melton, RG, Carola Hasan, A. Zoubek, et al.. (2005). Carboxypeptidase G2 rescue in patients with methotrexate intoxication and renal failure. British Journal of Cancer. 92(3). 480–487. 107 indexed citations
2.
Schwartz, Stefan, K. Börner, Karin Müller, et al.. (2004). Rescue with recombinant Carboxypeptidase G2 (CPG2) in high-dose methotrexate (HD-MTX) induced renal failure: Results in 42 patients from a German emergency protocol. Journal of Clinical Oncology. 22(14_suppl). 8067–8067. 1 indexed citations
3.
Schwartz, Stefan, K. Börner, Karin Müller, et al.. (2004). Rescue with recombinant Carboxypeptidase G2 (CPG2) in high-dose methotrexate (HD-MTX) induced renal failure: Results in 42 patients from a German emergency protocol. Journal of Clinical Oncology. 22(14_suppl). 8067–8067. 1 indexed citations
4.
5.
Melton, RG & R.F. Sherwood. (1996). Antibody-Enzyme Conjugates for Cancer Therapy. JNCI Journal of the National Cancer Institute. 88(3-4). 153–165. 81 indexed citations
6.
7.
Blakey, D C, P. J. Burke, D. Huw Davies, et al.. (1996). ZD2767, an improved system for antibody-directed enzyme prodrug therapy that results in tumor regressions in colorectal tumor xenografts.. PubMed. 56(14). 3287–92. 44 indexed citations
8.
Marshall, Damian, et al.. (1995). Galactosylated streptavidin for improved clearance of biotinylated intact and F(ab')2 fragments of an anti-tumour antibody. British Journal of Cancer. 71(1). 18–24. 31 indexed citations
9.
Springer, Caroline J., Robert I. Dowell, P. J. Burke, et al.. (1995). Optimization of Alkylating Agent Prodrugs Derived from Phenol and Aniline Mustards: A New Clinical Candidate Prodrug (ZD2767) for Antibody-Directed Enzyme Prodrug Therapy. Journal of Medicinal Chemistry. 38(26). 5051–5065. 64 indexed citations
10.
Niculescu‐Duvaz, Ion, Robert I. Dowell, D. Huw Davies, et al.. (1995). A new clinical candidate for antibody-directed enzyme prodrug therapy (ADEPT): ZD2767. Journal of Cancer Research and Clinical Oncology. 121(S1). A7–A7. 1 indexed citations
11.
Blakey, D C, Philip J. Burke, D. Huw Davies, et al.. (1995). Antibody-directed enzyme prodrug therapy (ADEPT) for treatment of major solid tumour disease. Biochemical Society Transactions. 23(4). 1047–1050. 11 indexed citations
12.
Eccles, Sue, et al.. (1994). Regression of established breast carcinoma xenografts with antibody-directed enzyme prodrug therapy against c-erbB2 p185.. PubMed. 54(19). 5171–7. 56 indexed citations
13.
14.
Antoniw, Pari, Springer Cj, K D Bagshawe, et al.. (1990). Disposition of the prodrug 4-(bis (2-chloroethyl) amino) benzoyl-L-glutamic acid and its active parent drug in mice. British Journal of Cancer. 62(6). 909–914. 38 indexed citations
15.
Searle, F, K D Bagshawe, R. Barbara Pedley, et al.. (1990). Carboxypeptidase G2 and trimetrexate cause growth delay of human colonic cancer cells in vitro. Biochemical Pharmacology. 39(11). 1787–1791. 2 indexed citations
16.
Bagshawe, K D, Springer Cj, F Searle, et al.. (1988). A cytotoxic agent can be generated selectively at cancer sites. British Journal of Cancer. 58(6). 700–703. 205 indexed citations
17.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by T W Strickland Breakdown of academic impact, for papers by Malaya Bhattacharya Breakdown of academic impact, for papers by Paul J. Kleindl Breakdown of academic impact, for papers by H.J. Schoemaker Breakdown of academic impact, for papers by Earl F. Albone Breakdown of academic impact, for papers by C. A. Waller Breakdown of academic impact, for papers by D. Deprez-De Campeneere Breakdown of academic impact, for papers by Samantha Lien Breakdown of academic impact, for papers by Linda Simpson‐Herren Breakdown of academic impact, for papers by Sudhir Shah
Rankless by CCL
2026